186 related articles for article (PubMed ID: 37285039)
1. CUL4A silencing attenuates cervical carcinogenesis and improves Cisplatin sensitivity.
Atri Y; Bharti H; Sahani N; Sarkar DP; Nag A
Mol Cell Biochem; 2024 May; 479(5):1041-1058. PubMed ID: 37285039
[TBL] [Abstract][Full Text] [Related]
2. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
3. Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism.
Jones TM; Espitia CM; Ooi A; Bauman JE; Carew JS; Nawrocki ST
Cell Death Dis; 2022 Apr; 13(4):350. PubMed ID: 35428778
[TBL] [Abstract][Full Text] [Related]
4. CUL4A promotes the invasion of cervical cancer cells by regulating NF-κB signaling pathway.
Mei Q; Ye LJ; Lin H; Chen CY
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10403-10409. PubMed ID: 33155196
[TBL] [Abstract][Full Text] [Related]
5. Lung tumourigenesis in a conditional Cul4A transgenic mouse model.
Yang YL; Hung MS; Wang Y; Ni J; Mao JH; Hsieh D; Au A; Kumar A; Quigley D; Fang LT; Yeh CC; Xu Z; Jablons DM; You L
J Pathol; 2014 Jun; 233(2):113-23. PubMed ID: 24648314
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
7. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
Shu XR; Wu J; Sun H; Chi LQ; Wang JH
Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
[TBL] [Abstract][Full Text] [Related]
8. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract][Full Text] [Related]
9. Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.
Englinger B; Mair M; Miklos W; Pirker C; Mohr T; van Schoonhoven S; Lötsch D; Körner W; Ferk F; Knasmüller S; Heffeter P; Keppler BK; Grusch M; Berger W
Br J Cancer; 2017 Feb; 116(4):489-500. PubMed ID: 28095394
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Cullin4A correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma.
Nakade H; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Miyao S; Sho M
Int J Clin Oncol; 2020 Mar; 25(3):446-455. PubMed ID: 31535245
[TBL] [Abstract][Full Text] [Related]
11. Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells.
Mehta H; Ambele MA; Mokgautsi N; Moela P
Cells; 2024 Apr; 13(8):. PubMed ID: 38667315
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of CCT3 promotes cervical cancer progression through FN1.
Dou L; Zhang X
Mol Med Rep; 2021 Dec; 24(6):. PubMed ID: 34651664
[TBL] [Abstract][Full Text] [Related]
13. CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal transition.
Pan Y; Wang B; Yang X; Bai F; Xu Q; Li X; Gao L; Ma C; Liang X
Sci Rep; 2015 Nov; 5():17006. PubMed ID: 26593394
[TBL] [Abstract][Full Text] [Related]
14. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.
Li R; Liu GZ; Luo SY; Chen R; Zhang JX
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4533-41. PubMed ID: 26698249
[TBL] [Abstract][Full Text] [Related]
15. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
[TBL] [Abstract][Full Text] [Related]
16. Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Uzawa K; Kasamatsu A; Baba T; Usukura K; Saito Y; Sakuma K; Iyoda M; Sakamoto Y; Ogawara K; Shiiba M; Tanzawa H
Cancer Med; 2013 Feb; 2(1):40-9. PubMed ID: 24133626
[TBL] [Abstract][Full Text] [Related]
17. LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel.
Mao BD; Xu P; Xu P; Zhong Y; Ding WW; Meng QZ
J Biosci; 2019 Jun; 44(2):. PubMed ID: 31180057
[TBL] [Abstract][Full Text] [Related]
18. The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas.
Tian XP; Qian D; He LR; Huang H; Mai SJ; Li CP; Huang XX; Cai MY; Liao YJ; Kung HF; Zeng YX; Xie D
Cancer Lett; 2014 Oct; 353(1):104-14. PubMed ID: 25045845
[TBL] [Abstract][Full Text] [Related]
19. Cancer-Derived Exosomal miR-651 as a Diagnostic Marker Restrains Cisplatin Resistance and Directly Targets ATG3 for Cervical Cancer.
Zhu X; Long L; Xiao H; He X
Dis Markers; 2021; 2021():1544784. PubMed ID: 34567283
[TBL] [Abstract][Full Text] [Related]
20. Cullin 4A is associated with epithelial to mesenchymal transition and poor prognosis in perihilar cholangiocarcinoma.
Zhang TJ; Xue D; Zhang CD; Zhang ZD; Liu QR; Wang JQ
World J Gastroenterol; 2017 Apr; 23(13):2318-2329. PubMed ID: 28428711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
